Modern Hybrid Imaging in Patients With OSCC (PETOSCC)
Modern Hybrid Imaging for Staging and Monitoring Patients With Oral Squamous Cell Carcinoma
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Studientyp
Studientyp
Einschreibung (Tatsächlich)
Einschreibung
Kontakte und Standorte
Studienorte
-
-
-
Würzburg, Deutschland, 97070
- Department of Cranio- and Maxillofacial Surgery
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Beschreibung
Inclusion Criteria:
- Histopathological proven head and neck carcinoma
- Written inform consent
- 18 years of age
Exclusion Criteria:
- Cancer of unknown primary
- En-bloc resection of lymph node levels
- Uncertainties regarding the removed lymph node levels
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Diagnostic accuracy of FGD-PET/CT to detect the primary tumor
Zeitfenster: 2013-2018
|
Visual assessment of FDG-PET/CT will be performed according to current guidelines.
The localization, expansion, and infiltration of osseous structures will be recorded.
The outcome measure is the correct diagnosis (1 = correct; 0 = false) with regards to the histopathological analysis.
The outcome measure will then be used to calculate the diagnostic accuracy of FDG-PET/CT to detect the primary tumor.
|
2013-2018
|
|
Diagnostic accuracy of FGD-PET/CT to detect lymph nodes metastases
Zeitfenster: 2013-2018
|
Visual assessment of FDG-PET/CT will be performed according to current guidelines.
The presence and number of nodal metastasis will be recorded for each cervical lymph node level.
The outcome measure is the correct diagnosis (1 = correct; 0 = false) with regards to the histopathological analysis.
The analysis will be performed on a patient level (lymph node metastasis yes/no), on the nodal metastatic involvement of cervical sides and lymph node levels.
The outcome measure will then be used to calculate the diagnostic accuracy of FDG-PET/CT to detect lymph node metastases.
|
2013-2018
|
|
Diagnostic accuracy of FGD-PET/CT to detect distant lymph node metastases.
Zeitfenster: 2013-2018
|
Visual assessment of FDG-PET/CT will be performed according to current guidelines.
The presence, localization and number of distant nodal metastasis will be recorded.
The outcome measure is the correct diagnosis (1 = correct; 0 = false) with regards to the histopathological analysis.
The outcome measure will then be used to calculate the diagnostic accuracy of FDG-PET/CT to detect lymph node metastases.
|
2013-2018
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Diagnostic accuracy of MRI to detect the primary tumor
Zeitfenster: 2013-2018
|
Visual assessment of MRI will be performed according to current guidelines.
The localization, expansion, and infiltration of osseous structures will be recorded.
The outcome measure is the correct diagnosis (1 = correct; 0 = false) with regards to the histopathological analysis.
The outcome measure will then be used to calculate the diagnostic accuracy of MRI to detect the primary tumor.
|
2013-2018
|
|
Diagnostic accuracy of MRI to detect lymph nodes metastases
Zeitfenster: 2013-2018
|
Visual assessment of MRI will be performed according to current guidelines.
The presence and number of nodal metastasis will be recorded for each cervical lymph node level.
The outcome measure is the correct diagnosis (1 = correct; 0 = false) with regards to the histopathological analysis.
The analysis will be performed on a patient level (lymph node metastasis yes/no), on the nodal metastatic involvement of cervical sides and lymph node levels.
The outcome measure will then be used to calculate the diagnostic accuracy of MRI to detect lymph node metastases.
|
2013-2018
|
|
Diagnostic accuracy of CT to detect the primary tumor
Zeitfenster: 2013-2018
|
Visual assessment of CT will be performed according to current guidelines.
The localization, expansion, and infiltration of osseous structures will be recorded.
The outcome measure is the correct diagnosis (1 = correct; 0 = false) with regards to the histopathological analysis.
The outcome measure will then be used to calculate the diagnostic accuracy of CT to detect the primary tumor.
|
2013-2018
|
|
Diagnostic accuracy of CT to detect lymph nodes metastases
Zeitfenster: 2013-2018
|
Visual assessment of CT will be performed according to current guidelines.
The presence and number of nodal metastasis will be recorded for each cervical lymph node level.
The outcome measure is the correct diagnosis (1 = correct; 0 = false) with regards to the histopathological analysis.
The analysis will be performed on a patient level (lymph node metastasis yes/no), on the nodal metastatic involvement of cervical sides and lymph node levels.
The outcome measure will then be used to calculate the diagnostic accuracy of CT to detect lymph node metastases.
|
2013-2018
|
|
Diagnostic accuracy of CT to detect distant lymph node metastases.
Zeitfenster: 2013-2018
|
Visual assessment of CT will be performed according to current guidelines.
The presence, localization and number of distant nodal metastasis will be recorded.
The outcome measure is the correct diagnosis (1 = correct; 0 = false) with regards to the histopathological analysis.
The outcome measure will then be used to calculate the diagnostic accuracy of CT to detect lymph node metastases.
|
2013-2018
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Ermittler
Ermittler
- Hauptermittler: Urs Müller-Richter, MD, DDS, PhD, Dpt. of CMF, University Hospital Wuerzburg
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Tatsächlich)
Primärer Abschluss
Studienabschluss (Tatsächlich)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- PETOSCC
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .